APC anti-human CD45RA and 11 more items

BioLegend Inc. was awarded contract A207_PO-0458034 by the University of Virginia on July 15, 2026, with a cumulative contract value of $3,961.75. The award encompasses the procurement of twelve distinct flow cytometry reagent products, including fluorescently-conjugated monoclonal antibodies targeting various human cell surface and intracellular antigens. The product line includes anti-human CD45RA, CD154 (CD40L), CD8, CD38, CD95 (Fas), CD45RO, CD69, and KLRG1 (MAFA) markers, along with intracellular staining reagents for Granzyme B, HLA-DR, FOXP3, and CD279 (PD-1). All materials are designated for delivery to Christine Nelson at the University of Virginia location in Virginia.

The contract involves the delivery of 18 individual units across the twelve line items, with unit prices ranging from $85.80 to $266.50. These immunological research reagents support flow cytometric analysis capabilities, likely for immunology or cellular research applications within the University of Virginia's research operations. The reagent portfolio covers markers associated with T-cell phenotyping, immune activation, exhaustion, and regulatory function, indicating use in advanced immunological research or clinical laboratory applications.